Advancements in the Management of Ovarian Cancer - Episode 4
Optimizing PARP Inhibitor Duration
Panelists discuss how the duration of PARP inhibitor (PARPi) therapy typically differs between the first-line and second-line settings in advanced ovarian cancer treatment.
Video content above is prompted by the following:
- Dr Herzog to ask Dr Chan: How long do you typically continue PARPi in the first-line setting? Does this differ in the second-line setting?
Related Content:
